Kura Oncology Stock Surges as Darlifarib + Cabozantinib Shows Strong Results in Tough Kidney Cancer Cases
Kura Oncology’s combo drug shrank kidney tumors in early trial, controlled cancer in most patients, stock jumped.
NOTRELOAD AI
Morgan Stanley Names Affirm as Top Pick with 26% Upside
Affirm is viewed as a strong buy with solid growth, stable funding, and potential upside as positive updates are expected soon.
Mizuho Turns Bearish on NXP: Auto Exposure and Weak 2026 Outlook Cited
Mizuho cut NXP to sell, slashing target to $188 on weak car demand and high inventory.
Goldman Sachs Highlights Corvus Pharmaceuticals as a Promising Oral Player in $24 Billion Atopic Dermatitis Market
Goldman sees Corvus as a buy: its oral eczema drug could rival Dupixent and grow into multiple diseases, boosting the stock potential.
AxoGen Stock Jumps as Cigna Adds Coverage for Avance Nerve Graft in Breast Reconstruction
AxoGen shares rose after Cigna will cover its nerve graft from Apr 2026, helping more patients get nerve repair after surgery.
Higher Aluminum Prices Help Alcoa, But Q1 Shipments Hit by Delays and Disruptions
Alcoa posted mixed Q1 results: profits rose, sales and shipments fell, but it expects recovery and stronger performance in Q2.